All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Sanofi's Myqorzo (aficamten) and Redemplo (plozasiran) win China approval for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome
Small molecule, cardiovascular, siRNA, hypertrophic cardiomyopathy, familial chylomicronaemia syndrome, cardiac myosin inhibitor - Read more

Santhera Pharmaceuticals' AGAMREE (vamorolone) receives Swissmedic approval for Duchenne muscular dystrophy treatment following Ph2b data
Small molecule, neurological, Duchenne muscular dystrophy, corticosteroid, orphan drug - Read more

THE GOOD
Business Development & Partnerships

BMS, Immunai collaborate on AI-powered immune system analysis using AMICA-OS platform, terms undisclosed
Research collaboration, AI/ML, immunology, drug discovery, data analytics - Read more

Cost Plus Drugs, Alchem Laboratories alliance to develop 86 essential medicines therapeutics
Strategic alliance, manufacturing, AI/ML, essential medicines, supply chain - Read more

InterAx Biotech, Alveus Therapeutics partner on metabolic disease small molecule candidate with undisclosed upfront payment
Research collaboration, metabolic disease, small molecule, licensing deal, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Ocugen's OCU410 gene therapy shows 46% lesion growth reduction in Ph2 trial for geographic atrophy
Gene therapy, ophthalmology, AAV vector, age-related macular degeneration, RORA target - Read more

Ipsen presents interim data on Dysport (abobotulinumtoxinA) for post-stroke spasticity from ongoing EPITOME study
Protein therapy, neurological, botulinum toxin, stroke, post-stroke spasticity - Read more

THE GOOD
Company Launches

adMare BioInnovations launches Ocythera to develop rare bone disease therapies using selective CYP26B1 inhibitors
Small molecule, rare disease, strategic, investment - Read more

Zydus Lifesciences completes acquisition of Agenus' biologics facilities, launches Zylidac Bio
Biologics, oncology, strategic, major transaction, operational - Read more

THE GOOD
Earnings & Finances

ImmunityBio reports $113M preliminary net product revenue, representing 700% year-over-year increase with strong ANKTIVA sales momentum
Interleukin-15 superagonist, oncology, financial, revenue impact - Read more

THE GOOD
Fundraises

Novo Nordisk Foundation commits $856M funding for Danish life science incubator BioInnovation Institute
Incubator, platform technology, AI/ML platform, life science services - Read more

BriaCell Therapeutics raises $30M public offering, clinical-stage cancer immunotherapy development
Cancer, immunotherapy, clinical-stage, oncology - Read more

THE GOOD
Investments

BD invests $110M to expand Nebraska syringe production amid rising GLP-1 and biologics demand
Biologics, metabolic disorders, operational, major transaction, manufacturing expansion - Read more

THE GOOD
Mergers & Acquisitions

Boston Scientific to acquire Penumbra for $14.5B to expand vascular thrombectomy and embolization portfolio
Medical devices, cardiovascular, strategic, major transaction - Read more

Oxford Biomedica confirms takeover talks with private equity group EQT after rejecting previous low offers
Viral vector, strategic, major transaction, financial - Read more

Sanofi reportedly prepares renewed takeover bid for Ocular Therapeutix after rejecting $16-per-share offer
Ophthalmic therapeutics, eye disease, strategic, major transaction - Read more

THE GOOD
Product Launches

Sun Pharma announces availability of UNLOXCYT for advanced cutaneous squamous cell carcinoma in U.S.
Monoclonal antibody, oncology, strategic, operational - Read more

THE GOOD
Strategic Plans

Fosun Pharmaceutical aims to become global drug innovator, generating $5.9B revenue in 2024
Multi-modality, oncology, strategic, financial - Read more [Paywall]

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Lawsuits

Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk alleging coordinated antitrust efforts suppressing GLP-1 competition
GLP-1 agonist, metabolic disease, competitive, antitrust - Read more

THE BAD
Politics & Policy

Trump unveils Great Healthcare Plan targeting insurers, expanding Most Favored Nation drug pricing beyond 17 pharma companies
Pharmaceutical industry, strategic, regulatory, financial - Read more

THE BAD
Regulatory

FDA orders Sanofi, GSK, AstraZeneca and CSL to add febrile seizure warnings on flu vaccine labels
Vaccine, infectious disease, regulatory, operational - Read more

FDA issues untitled letters to ImmunityBio and BeOne Medicines over misleading promotional materials for drugs
Immunotherapy, oncology, regulatory, operational - Read more

FDA delays decision for Eli Lilly's obesity pill orforglipron until April 2026, extends other drug reviews
Small molecule, metabolic disease, regulatory, strategic - Read more

THE BAD
Strategic Plans

Astellas CEO rejects "rescue BD" acquisitions despite $6B Xtandi patent cliff approaching in 2027
Antibody-drug conjugate, oncology, strategic, patent cliff - Read more

THE UGLY
Politics & Policy

RFK Jr. dismisses half of childhood vaccine injury panel members, signalling potential US vaccine policy changes
Vaccine, infectious disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here